Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 3314

Journal of Biotechnology & Biomaterials received 3314 citations as per Google Scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
Recommended Journals
Share This Page

HRA2pl production in tobacco plants by transient transformation of plants, a fusion inhibitor in the hMPV infection in HEp-2 cell line

5th World Congress on Biotechnology

Verónica Araceli Márquez-Escobar, Rocío Tirado Mendoza, Daniel Ernesto Noyola-Cherpitel, Abel Gutiérrez-Ortega and Ángel Gabriel Alpuche-Solís

Posters: J Biotechnol Biomater

DOI: 10.4172/2155-952X.S1.028

Abstract
Among the available systems for the expression of recombinant proteins, the use of plants as bioreactors is one of the most promising ones, since their use reduce the production costs and post-translational modifications requested for biological activity are achieved in plants, in addition, none of few simple purification steps are needed to deliver the pharmaceutical proteins in the mucous membranes so that they may be used as antiviral peptides or vaccines against respiratory tract infectious agents. The etiologic agents that cause respiratory illnesses are mainly bacteria and viruses; the latter are responsible for 50- 60% of acute respiratory infections (IRAs). Human metapneumovirus (hMPV) is responsible for acute respiratory infections and at least for 5-10% of hospitalizations in young children, mainly in children under three years old, the elderly and immunocompromised patients. Currently there is no treatment or vaccine available against hMPV. It has been demonstrated that the fusion of the hMPV to the host cell can be inhibit by a peptide analogous to F protein. We designed a synthetic gene expressing this peptide named HRA2pl and by a transient viral expression system (Magnifection), the recombinant peptide was produced in tobacco plants. Extraction of total soluble protein was performed and its functionality in vitro was examined by a Dot blot and Western blot. Its efficacy as an antiviral was evaluated by replication inhibition assays in HEp-2. This peptide could be an alternative for prevention and reduction of the transmission of hMPV
Biography
Verónica Araceli Márquez Escobar has completed her master degree in Molecular Biology at IPICYT, San Luis Potosí, México and she is doing her a PhD in the same institute. Her research work has been focused in the production in plants of an antiviral peptide against a respiratory pathogen called human metapneumovirus. The research group of Dr. Ángel Gabriel Alpuche Solís (her supervisor), has been working on the production of biopharmaceuticals in plants such as antivirals peptides and vaccines against infectious diseases and published more than 45 referred papers.
Top